These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17898921)

  • 1. Adherence to alendronate in male veterans.
    Hansen KE; Swenson ED; Baltz B; Schuna AA; Jones AN; Elliott ME
    Osteoporos Int; 2008 Mar; 19(3):349-56. PubMed ID: 17898921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines.
    Cheng TT; Yu SF; Hsu CY; Chen SH; Su BY; Yang TS
    Clin Ther; 2013 Jul; 35(7):1005-15. PubMed ID: 23831360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors and Outcomes Associated With Adherence to Weekly Alendronate in US Military Veterans: Clinical Research Study.
    Bou Malham S; Bowe B; Sen SK; Zhang RM; Sterkel B; Dunn JP
    J Prim Care Community Health; 2019; 10():2150132719884300. PubMed ID: 31779523
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of mandatory generic substitution on the safety of alendronate and patients' adherence.
    Lai PS; Chua SS; Chong YH; Chan SP
    Curr Med Res Opin; 2012 Aug; 28(8):1347-55. PubMed ID: 22746354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
    Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
    Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
    Landfeldt E; Lang A; Robbins S; Ström O
    Calcif Tissue Int; 2011 Sep; 89(3):234-45. PubMed ID: 21695544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting.
    Downey TW; Foltz SH; Boccuzzi SJ; Omar MA; Kahler KH
    South Med J; 2006 Jun; 99(6):570-5. PubMed ID: 16800411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway.
    Devold HM; Furu K; Skurtveit S; Tverdal A; Falch JA; Sogaard AJ
    Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):297-304. PubMed ID: 22237942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
    Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
    Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alendronate for osteoporosis in men with androgen-repleted hypogonadism.
    Shimon I; Eshed V; Doolman R; Sela BA; Karasik A; Vered I
    Osteoporos Int; 2005 Dec; 16(12):1591-6. PubMed ID: 16362147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients' reasons for adhering to long-term alendronate therapy.
    Pepe J; Cipriani C; Cecchetti V; Ferrara C; Della Grotta G; Danese V; Colangelo L; Minisola S
    Osteoporos Int; 2019 Aug; 30(8):1627-1634. PubMed ID: 31089764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
    Finkelstein JS; Hayes A; Hunzelman JL; Wyland JJ; Lee H; Neer RM
    N Engl J Med; 2003 Sep; 349(13):1216-26. PubMed ID: 14500805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study.
    Olszynski WP; Davison KS; Ioannidis G; Brown JP; Hanley DA; Josse RG; Murray TM; Papaioannou A; Sebaldt RJ; Tenenhouse AM; Petrie A; Goldsmith CH; Adachi JD
    Osteoporos Int; 2006 Feb; 17(2):217-24. PubMed ID: 15997420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Side Effects, Physician Involvement, and Patient Perception in Non-Adherence with Oral Bisphosphonates.
    Goldshtein I; Rouach V; Shamir-Stein N; Yu J; Chodick G
    Adv Ther; 2016 Aug; 33(8):1374-84. PubMed ID: 27329383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
    Lu PY; Hsieh CF; Tsai YW; Huang WF
    Clin Ther; 2011 Sep; 33(9):1173-9. PubMed ID: 21849210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of testosterone, alendronate, and a combination of both therapies in men with low bone mineral density.
    Welch BJ; Denke MA; Kermani A; Adams-Huet B; Gazmen NM; Gruntmanis U
    J Investig Med; 2007 May; 55(4):168-73. PubMed ID: 17651670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alendronate for the treatment of osteoporosis in men.
    Olszynski WP; Davison KS
    Expert Opin Pharmacother; 2008 Feb; 9(3):491-8. PubMed ID: 18220499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compliance with alendronate 10 treatment in elderly women with postmenopausal osteoporosis.
    Sewerynek E; Dabrowska K; Skowrońska-Jóźwiak E; Zygmunt A; Lewiński A
    Endokrynol Pol; 2009; 60(2):76-81. PubMed ID: 19396749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.